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Gut dysfunction in patients with multiple sclerosis
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Objectives Bowel and bladder symptoms are highly
prevalent in patients with multiple sclerosis (MS). Bladder
dysfunction (affecting 75% of these patients) is caused
by disease in the spinal cord, whilst the pathophysiology
of bowel dysfunction is unknown. Pathways regulating
both the organs lie in close proximity to the spinal cord,
and coexistence of their dysfunction might be the result
of a common pathophysiology. If so, the prevalence
of bladder symptoms should be greater in patients with
MS and bowel symptoms. This hypothesis is tested
in the study. We also evaluated how patient-reported
symptoms quantify bowel dysfunction.
Patients and methods The Neurogenic Bowel
Dysfunction questionnaire and the presence of bladder
symptoms were recorded in 71 patients with MS and
bowel symptoms. Disability, a surrogate clinical measure of
spinal cord disease, was assessed using the Expanded
Disability Status Scale. Bowel and bladder symptoms were
quantified by patient-reported frequency, expressed in time
percentage (0, 25, 50, 75 or 100% of the time the symptom
was perceived), and patient-reported severity on a visual
analogue scale between 0 and 100.
Results The prevalence of bladder symptoms was 85%,
which is higher than that expected in an unselected
population of patients with MS. Neurogenic Bowel
Dysfunction score was significantly correlated with both
patient-reported frequency (r=0.860, P<0.0001) and
severity of bowel symptoms (r=0.659, P= <0.0001),
as well as with the Expanded Disability Status Scale
(r=0.526, P<0.0001).
Conclusion Our findings suggest that gut dysfunction
in patients with MS is secondary to spinal cord disease.
Patient-reported bowel symptoms quantify bowel
dysfunction well. Eur J Gastroenterol Hepatol
25:1044–1050 c 2013 Wolters Kluwer Health | Lippincott
Williams & Wilkins.
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Introduction
Bowel symptoms (constipation and/or faecal inconti-
nence) affect up to two-thirds of patients with multiple
sclerosis (MS) [1], causing social isolation [2] and general
reduction of quality of life [3,4]. Their origin is multi-
factorial and polypharmacy, disability, comorbidities and
parity may have a causative role [5], but from the neuro-
logical standpoint MS can affect both extrinsic autonomic
and voluntary control of the bowel. The effects on the
end-organ include alterations of gut motility, anorectal
sensation/coordination and anal sphincter control [6], but
the neurological pathway that causes these disturbances is
still unknown. This is mirrored in the lack of standards of
treatment. MS symptoms relief, in the absence of a treat-
ment for the primary neurological injury, is of paramount
importance, but the area of bowel dysfunction remains the
‘Cinderella’ of MS research.
In contrast, bladder dysfunction, affecting around 75%
of the patients with MS [7], has been well characterized.
It is established that MS plaques in the spinal cord are
central to cause urinary symptoms [8], and their treat-
ment has been rationalized and standardized [9]. Neuro-
logical pathways regulating pelvic organs are in close
proximity within the spinal cord; thus, it is unsurprising
that bowel and bladder symptoms often coexist in patients
with MS [1,10,11]. When this is the case, it could be that
sclerotic plaques in the spinal cord simultaneously affect
bladder and bowel function. However, in a study of MS
patients with bladder dysfunction [12], the prevalence of
bowel symptoms was only around 50%. This apparent
discrepancy could be explained by the presence of the
gut’s enteric nervous system, which would allow pre-
servation of some bowel function in the presence of
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altered extrinsic hindgut modulation. This compensatory
mechanism is not available to the bladder [13]. There-
fore, we hypothesized that if bowel and bladder dysfunc-
tion can be caused by the same MS-related neurological
alteration, in a selected population of patients with MS
with bowel symptoms, a higher prevalence of bladder
symptoms should be observed than that in the general
MS population. The aim of the study was to test this
hypothesis. We also analysed how well bowel dysfunction
is assessed by patient-reported bowel symptoms, and any
correlations between patient-reported bowel and bladder
symptoms.
Anatomical considerations
The neural control of defecation is not clearly defined,
but the centre concerned with it probably lies in the
pons, and is under conscious cortical modulation [14];
defecation is also influenced by supraspinal centres [15].
It has been demonstrated that the spinal pathway for
defecation, operating through sacral roots (S2–S4), lies in
the lateral column of the cord, in close proximity to those
pathways important for bladder control [15–17].
The neural pathways involved in physiological bladder
control operate through complex bulbospinal–bulbar
pathways, in close proximity to the lateral pyramidal
tracts, and are mediated peripherally through the sacral
roots S2–S4 [18,19]. Cortical voluntary control of
micturition is established by connection of the frontal
cortex to the micturition centre in the pons [20].
Types of multiple sclerosis
MS is characterized by an autoimmune response that
results in the disruption of the myelin sheath in the
central nervous system (demyelination), and the subse-
quent gliosis leads to the widespread occurrence of
plaques in the white matter of the central nervous system
that affects signal transmission. The natural history of the
disease is of a progressive accumulation of neurological
symptoms leading to severe disability. On the basis of the
rapidity of progression and of accumulation of disability,
MS is classified as relapsing remitting (most common,
where symptoms appear and fade away), secondary pro-
gressive (usually follows relapsing remitting, character-
ized by a sustained build up of disability, independent of
any relapses) and primary progressive (where the disease
is progressive from the start).
Patients and methods
The Ethics Committee of University College of London
granted Ethical approval (REC reference number:
08/h07164/7), and patients who participated in the study
signed a consent form. Entry criteria included a definite
diagnosis of MS and normal bowel function before the
onset of MS. Exclusion criteria included: concomitant
primary bowel pathology, comorbidities (i.e. diabetes,
thyroid dysfunction, coeliac disease, prostate hypertro-
phy, etc.) and sphincter injury. These were ruled out in all
patients by means of negative investigation (colonoscopy,
radiological or laboratory test) as appropriate. We
recruited 71 consecutive patients with MS (55 women,
aged 43±9, median disease duration 78±43 months)
referred for bowel symptoms to a specialist neurogas-
troenterology clinic, in a tertiary referrals unit. None of
the patients fulfilled any of the exclusion criteria.
Assessment of disability
Disability was measured with the Expanded Disability
Status Scale (EDSS) [21], which is commonly used in
patients with MS both in research and clinical practice.
The EDSS scale ranges from 0 to 10 in 0.5U increments
that represent higher levels of disability and is principally
based on ambulatory ability of the patient. For scores
between 1 and 4.5 the patient is able to walk, and the
score is mainly based on evaluation of eight functional
systems: pyramidal, cerebellar, brain stem, sensory, bowel
and bladder, visual function, cerebral and mental func-
tion, and lastly any other system. With an EDSS above 5,
mobility is impaired, at 7, the patient is wheelchair-
bound and for scores above 8, the patient is bed-bound.
Ten is death because of MS.
Disability is thought to be dependent on spinal cord
involvement in MS, a common site of demyelinating
lesions [22]. Although there is no correlation between the
load of cord lesions on imaging and MS symptoms, it
appears that spinal cord atrophy (signifying axonal loss) is
a good radiological marker that correlates with MS
symptoms [23,24]. Furthermore, EDSS correlates with
spinal cord atrophy [23–25] and is a reflection of diffusion
of spinal cord disease [26].
Symptoms assessments
Neurogenic Bowel Dysfunction questionnaire
No bowel symptoms questionnaire has been specifically
validated in MS. Considering that constipation and faecal
incontinence are often coexisting and alternating, we
aimed to use an instrument that would evaluate both, as
well as their impact on quality of life.
We therefore used the Neurogenic Bowel Dysfunction
(NBD) questionnaire, which has been designed and
validated in patients with spinal cord injury [27].
It includes questions about background parameters
(n=8), faecal incontinence (n=10), constipation (n=10),
obstructed defecation (n=8) and impact on quality of life
(n=3). The NBD score weights each symptom of bowel
dysfunction in relation to its impact on quality of life, and
scores are categorized as follows: 0 to 6 very minor
dysfunction, 7 to 9 minor dysfunction, 10 to 13 moderate
dysfunction and 14 to 47 severe dysfunction.
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Patient-reported symptoms of bowel and bladder
dysfunction
Patient-reported outcome measures are increasingly used
in medical studies [28–30] and were assessed within
a structured interview, conducted in the outpatient
clinic. The alternating and fluctuating pattern of bowel
habit in patients with MS is similar to that of irritable
bowel syndrome. In patients with this condition, the
product of frequency and severity of symptoms has been
employed to quantify bowel function [31,32]. Therefore,
each patient was asked what proportion of time of his or
her life was affected by constipation and/or faecal
incontinence, with five possible answers (0, 25, 50, 75
or 100% of the time). We then assessed severity by asking
patients to use a visual analogue scale from 0 to 100, with
0 representing absence of symptoms, and 100 if the
patient thought that bowel symptoms were the worst
possible. These data were collected by a doctor
experienced in assessing bowel symptoms (G.P.).
The presence of bladder symptoms and on-going treatment
(antimuscarinic agents, use of intermittent self-catheter-
ization, permanent catheter) was ascertained from the
patient’s history and clinical notes. Urgency was defined as
a sudden compelling desire to pass urine that is difficult to
defer [33]; urge urinary incontinence was defined as
incontinence accompanied by or immediately preceded
by urgency. The patient was also asked about difficulty of
initiating bladder voiding (hesitancy), interruption of flow,
sense of incomplete bladder emptying and use of pads.
We aimed to quantify bladder and bowel dysfunction
uniformly. Therefore, we asked the proportion of time a
patient perceived bladder symptoms affected his or her
life, with five possible answers (0, 25, 50, 75 or 100% of
the time). Severity was assessed on a visual analogue scale
from 0 to 100, similarly to bowel symptoms. These data
were collected by a doctor experienced in assessing
bladder symptoms (J.P.).
Study design and statistical analysis
Scores from questionnaires and outcome of outpatient
interviews were prospectively collected. Prevalence
of bladder dysfunction was established as the presence
of at least one urinary symptom at least 25% of the time.
Data were either ordinal or not normally distributed
(according to Kolmogorov–Smirnov test); thus, they are
expressed as median and interquartile ranges and
nonparametric tests were used. Age and disease duration
are presented as mean and SD. Correlations between our
parameters (EDSS, MS type and duration, NBD and
patient-reported bowel and bladder symptoms) were
evaluated using Spearman’s rank test.
To evaluate how patient-reported symptoms quantified
bowel dysfunction, we analysed correlations between NBD
scores and patient-reported bowel symptoms with the
Spearman’s rank test (r=correlation coefficient). The
values of the NBD score for each of the four different
categories of patient-reported frequency of bowel symp-
toms (25, 50, 75 or 100%) were compared with the
Kruskal–Wallis test.
Statistical significance was two-sided, and declared for
P values of 0.05 or less. Statistical analysis was performed
using the statistical software package IBM SPSS statistics
v21 for Mac (IBM, Armonk, New York, USA).
Results
Patients’ characteristics are reported in Table 1.
Of the interviewed patients, 85% had some degree of
urinary symptoms.
Table 1 Patients’ baseline characteristics
All cohort (n=71,
55 female)
Primary progressive MS
(n=16, 13 female)
Secondary progressive MS
(n=30, 23 female)
Relapsing remitting MS
(n=25, 19 female)
Age (years) 43±9 39±10 44±8 45±8
Disease duration (months) 78±43 58 (33.5–107.5) 84.5 (55–104) 67 (45–89)
EDSS 3 (1–4) 1.5 (0.5–3) 3.5 (1–4.5) 3.5 (1.75–4)
Neurogenic Bowel Dysfunction score 8 (6–13) 5.5 (4–8) 10.5 (6–14) 8 (7–18)
EDSS, Expanded Disability Status Scale; MS, multiple sclerosis.
Table 2 Correlation analysis of bowel symptoms and patients characteristics
Relapsing remitting MS
(25)
Primary progressive MS
(16)
Secondary progressive MS
(20)
Disease duration (70, 47–100)
(months)
EDSS
(3, 1–4)
Neurogenic Bowel Dysfunction score r=0.168
P=0.161
r= –0.355
P=0.002
r=0.137
P=0.253
r=0.125
P=0.297
r=0.526
P<0.0001
Bowel symptoms patient-reported
frequency
r=0.168
P=0.161
r= –0.351
P=0.003
r=0.153
P=0.203
r=0.169
P=0.160
r=0.645
P<0.0001
Bowel symptoms patient-reported
severity
r=0.21
P=0.873
r= –0.120
P=0.318
r=0.81
P=0.500
r=0.79
P=0.512
r=0.112
P=0.352
Data are reported as median and range.
Spearman’s rank correlation coefficients (r) are given along with P value.
Statistically significant correlations are shown in bold.
EDSS, Expanded Disability Status Scale; MS, multiple sclerosis.
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Correlation analysis
Correlation of EDSS, MS type and duration, NBD and
patient-reported bowel symptoms is summarized in
Table 2. Figure 1 shows the graphical correlation between
EDSS and NBD.
Correlation between bowel and bladder patient-reported
symptoms is summarized in Table 3 and Fig. 2.
Evaluation of patient-reported symptoms
NBD scores were correlated with patient-reported fre-
quency (r=0.860, P<0.0001) and severity (r=0.659,
P<0.0001) of bowel symptoms.
There was significant difference between the values of
NBD scores in the four categories of patient-reported
frequency of bowel symptoms (Table 4 and Fig. 3).
Discussion
In our cohort, the prevalence of bladder dysfunction was
85%, which is higher than that expected in an unselected
MS population, confirming our hypothesis and suggesting
common pathophysiology of bowel and bladder dysfunc-
tion. Also, the NBD score was strongly correlated with
the EDSS, which is a clinical indicator of spinal cord
involvement in MS. These findings suggest that gut
dysfunction in patients with MS is secondary to spinal
cord involvement of the disease.
In patients with primary progressive disease, there was an
inverse relationship with bowel symptoms (i.e. the higher
the EDSS the lower the level of symptoms). The lower
level of disability of this subgroup might explain this;
however, it might just indicate that patients with other
MS types have more bowel symptoms.
Fig. 1
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Table 3 Correlation analysis of bowel and bladder symptoms
Bladder symptoms
Bowel symptoms Patient-reported frequency (50%, 0–100%) Patient-reported severity (41, 0–93)
Neurogenic Bowel Dysfunction score (8, 1–30) r=0.342
P=0.003
r=0.659
P<0.001
Patient-reported frequency (50%, 25–100%) r=0.367
P=0.002
r=0.300
P=0.011
Patient-reported severity (58, 96–11) r=0.300
P=0.011
r=0.463
P<0.0001
Spearman’s rank correlation coefficient and P values are given for correlation analysis of variable of bowel and urinary dysfunction.
All correlations were statistically significant.
Fig. 2
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Patient-reported frequency and severity of bowel and
bladder symptoms were correlated.
With regards to bowel symptoms evaluation, simple
questioning of patient-reported frequency and severity
of bowel symptoms is as accurate as a validated ques-
tionnaire. Therefore, physicians, in the clinical setting,
would be able to assess the impact of bowel dysfunction
by determining the percent of time these symptoms are
perceived. In contrast, the NBD score could be used to
improve the quality of bowel studies in patients with MS.
The main strength of this study is the methodology used
to evaluate our hypothesis, which is supported by anato-
mical considerations and supportive evidence. Also low
level of disability in this cohort reduced the effect of
confounders such as reduced mobility and polypharmacy.
There are also several limitations. A relevant one is the
lack of a control group without bowel symptoms. Un-
fortunately, although bowel symptoms are so prevalent, it
is very difficult to recruit such a reference population in
a study.
It is well known that antimuscarinic drugs used for
urological symptoms can cause constipation, and this
could be a confounding factor affecting our findings. Still,
in the study by Chia et al. [12], where patients were
receiving pharmacological treatment for bladder dysfunc-
tion, no higher occurrence of bowel symptoms was
observed.
Unfortunately we did not record drugs taken at the time.
But antimuscarinics could have hypothetically masked
symptoms of faecal incontinence, ultimately making
patients overall more constipated. Still, patients with
higher disability had high scores in both constipation and
incontinence, suggesting that the confounder effect of
drugs, if present, was minimal. In some of our male
patients, the presence of undetected prostate hyper-
trophy might have also contributed to the presence
of bladder symptoms.
Another limitation of this study is that bladder symptoms
were not quantified with a standard questionnaire. The
correlation of patient-reported bowel and bladder symp-
toms merits further evaluation, employing a validated
urological questionnaire.
An element that merits further discussion is the low level
of disability in our cohort. In fact for an EDSS of less than
5, functional systems other than the spinal cord are
relevant. Overall, our findings suggest that, although the
cause of bowel dysfunction in patients with MS is
multifactorial, the spinal cord plays a central role from
the neuropathophysiology standpoint. Reflex activity in
the spinal cord has a crucial role in regulating bowel
function, and this has been widely demonstrated in pa-
tients with spinal cord injury [34–36], with whom MS
patients share many similarities. Physiological studies in
MS showed that the conduction in the central motor
pathways to the sphincteric sacral neurons is delayed [37].
In addition, somatosensory evoked potentials from the
spinal cord to the brain have been shown to be delayed in
MS compared with controls, with normal potentials
recorded at the lumbar spine [38].
The loss of cortical modulation of spinal reflex activity
can result in autonomic dysfunction of colonic motility,
resulting in a prevalence of the sympathetic tone and
slow colonic transit (constipation) [38], or in the loss of
inhibition of parasympathetic output, uncontrolled colo-
nic contractions and diarrhoea [39]. This could be the
result of unopposed parasympathetic stimulation of the
vagus nerve that supplies the colon up to the splenic
flexure.
In addition to the motor effects, anorectal hyposensitivity
is another common feature of MS and spinal cord injuries
that can affect the anorectum [1].
Disability measured with EDSS (reflective of the spinal
cord involvement in MS) has been found consistently, as
Table 4 Comparison of Neurogenic Bowel Dysfunction scores
between the four categories of patient-reported frequency
of bowel symptoms
Bowel symptoms patient-reported
frequency (%)
Neurogenic Bowel
Dysfunction score
Kruskal–
Wallis test
25 4 (3–5.5) P<0.001
50 8 (6–9.5)
75 17 (11–20)
100 26.5 (21–29.5)
Values of the Neurogenic Bowel Dysfunction scores for each group of bowel
symptoms patient-reported frequency are shown.
Fig. 3
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in our study, to correlate with bowel symptoms [10,11]. It
could be that there is a specific pattern of neurological
deficit resulting in lower limb dysfunction and bowel
symptomatology, and/or that difficulty accessing the
toilet contributes to bowel symptoms.
A parallel phenomenon to bowel and bladder dysfunction,
secondary to spinal cord disease, could be pelvic floor
incoordination. In fact, the loss of cortical modulation of
spinal reflexes due to MS plaques may result in auto-
nomous functioning of the bladder, explaining bladder
detrusor dyssynergia [40]. This is the uncoordinated
contraction of the detrusor muscle when the bladder
attempts voiding. A similar and parallel mechanism might
result in pelvic floor dyssynergia (uncoordinated contrac-
tion of the puborectalis and abdominal muscles on voiding
the rectum), causing obstructed defecation and incom-
plete rectal emptying [41,42]. A full rectum might in turn
precipitate urgency and faecal incontinence in the
presence of anal sphincter weakness and anorectal hypo-
sensitivity or rectoanal incoordination [43], explaining
coexistence of constipation and faecal incontinence in
patients with MS. Pelvic floor dyssynergia might be also
behavioural, and reversible with biofeedback [44]. Suc-
cessful biofeedback in non-neurological patients is asso-
ciated with gut-specific changes in autonomic outflow to
the large bowel, with spinal efferents playing a key
role [45]. Therefore, improvement of bowel symptoms
with biofeedback might be attributed to the ability to
recruit alternative neurological pathways through residual
spinal cord function. This also suggests that neuromodula-
tion in patients with residual spinal cord function could
represent a targeted treatment option.
To improve our understanding of the natural history and
aetiology of bowel dysfunction in MS, it would be helpful
to correlate imaging and physiological studies in MS
patients with bowel symptoms. Stratification of patients
according to spinal cord disease, as clinically measured by
the EDSS, could aid in the stratification of patients for
targeted treatment.
Conclusion
Our findings and available evidence suggest that spinal
cord involvement in MS is central to determination of
bowel symptoms. This is highly relevant both to improve
our understanding of bowel dysfunction in MS and in the
development of further studies on the subject that should
stratify patients on the basis of the clinical extent of
spinal cord disease (EDSS). Physicians can easily assess
lower limb function (a major determinant of EDSS), and
a pragmatic treatment algorithm based on this parameter
could be employed to improve bowel care in MS patients
in the community. Residual spinal cord function could be
a target of treatments such as neuromodulation, phy-
siotherapy or biofeedback. The knowledge generated by
studies on MS-related bowel dysfunction can also improve
our understanding of the neural control of defecation and
treatment of functional bowel disorders.
Finally, patient-reported frequency of bowel symptoms
evaluates bowel dysfunction well, and so it is a valuable
tool in the clinical setting. Equally, the Neurogenic Bowel
Dysfunction score could be used to improve the quality
of bowel studies in patients with MS.
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